Literature DB >> 26525415

Circulating microRNAs as novel biomarkers for bone diseases - Complex signatures for multifactorial diseases?

Matthias Hackl1, Ursula Heilmeier2, Sylvia Weilner3, Johannes Grillari4.   

Abstract

Biomarkers are essential tools in clinical research and practice. Useful biomarkers must combine good measurability, validated association with biological processes or outcomes, and should support clinical decision making if used in clinical practice. Several types of validated biomarkers have been reported in the context of bone diseases. However, because these biomarkers face certain limitations there is an interest in the identification of novel biomarkers for bone diseases, specifically in those that are tightly linked to the disease pathology leading to increased fracture-risk. MicroRNAs (miRNAs) are the most abundant RNA species to be found in cell-free blood. Encapsulated within microvesicles or bound to proteins, circulating miRNAs are remarkably stable analytes that can be measured using gold-standard technologies such as quantitative polymerase-chain-reaction (qPCR). Nevertheless, the analysis of circulating miRNAs faces several pre-analytical as well as analytical challenges. From a biological view, there is accumulating evidence that miRNAs play essential roles in the regulation of various biological processes including bone homeostasis. Moreover, specific changes in miRNA transcription levels or miRNA secretory levels have been linked to the development and progression of certain bone diseases. Only recently, results from circulating miRNAs analysis in patients with osteopenia, osteoporosis and fragility fractures have been reported. By comparing these findings to studies on circulating miRNAs in cellular senescence and aging or muscle physiology and sarcopenia, several overlaps were observed. This suggests that signatures observed during osteoporosis might not be specific to the pathophysiology in bone, but rather integrate information from several tissue types. Despite these promising first data, more work remains to be done until circulating miRNAs can serve as established and robust diagnostic tools for bone diseases in clinical research, clinical routine and in personalized medicine.
Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Aging; Biomarkers; Bone disease; Circulating microRNA; Osteoporosis; Sarcopenia

Mesh:

Substances:

Year:  2015        PMID: 26525415     DOI: 10.1016/j.mce.2015.10.015

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  66 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 2.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

Review 3.  Epigenetics of Skeletal Diseases.

Authors:  Alvaro Del Real; Leyre Riancho-Zarrabeitia; Laura López-Delgado; José A Riancho
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

Review 4.  Regulation of Bone Metabolism by microRNAs.

Authors:  Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2018-02       Impact factor: 5.096

5.  Circulating microRNAs, miR-10b-5p, miR-328-3p, miR-100 and let-7, are associated with osteoblast differentiation in osteoporosis.

Authors:  Ruisong Chen; Xin Liao; Fengrong Chen; Bowen Wang; Jianming Huang; Guojian Jian; Zheyuan Huang; Ganghui Yin; Haoyuan Liu; Dadi Jin
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

6.  Circulating MiR-21 expression is upregulated after 30 days of head-down tilt bed rest.

Authors:  D A Bemben; B S Baker; S R Buchanan; C J Ade
Journal:  Osteoporos Int       Date:  2021-01-11       Impact factor: 4.507

7.  MiR-148a the epigenetic regulator of bone homeostasis is increased in plasma of osteoporotic postmenopausal women.

Authors:  Ajda Bedene; Simona Mencej Bedrač; Lea Ješe; Janja Marc; Peter Vrtačnik; Janez Preželj; Tomaž Kocjan; Tilen Kranjc; Barbara Ostanek
Journal:  Wien Klin Wochenschr       Date:  2016-11-29       Impact factor: 1.704

Review 8.  MicroRNAs in bone diseases.

Authors:  L Gennari; S Bianciardi; D Merlotti
Journal:  Osteoporos Int       Date:  2016-11-30       Impact factor: 4.507

Review 9.  Epigenetic regulation of bone remodeling by natural compounds.

Authors:  Nishikant Raut; Sheila M Wicks; Tempitope O Lawal; Gail B Mahady
Journal:  Pharmacol Res       Date:  2019-07-14       Impact factor: 7.658

Review 10.  Potential Role of MicroRNA in the Anabolic Capacity of Skeletal Muscle With Aging.

Authors:  Lee M Margolis; Donato A Rivas
Journal:  Exerc Sport Sci Rev       Date:  2018-04       Impact factor: 6.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.